Reduced levels of high-density lipoproteins (HDL) in middle age could raise the risk of memory loss and dementia in later life, new research suggests.

A study reported in the Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association found that low levels of HDL cholesterol may be used as a predictor of neurodegenerative risk - particularly memory loss - in patients by the time they reach the age of 60.

Lead author of the report Dr Archana Singh-Manoux, senior research fellow with the French National Institute for Health and Medical Research (INSERM, France) and the University College London, commented: "Memory problems are key in the diagnosis of dementia."

The research, which involved 3,673 participants, revealed that at age 55 patients with low HDL cholesterol were 27 per cent more likely to suffer from memory loss than those with high levels of HDL.

At the age of 60, participants with low HDL had a 53 per cent increased risk of memory loss compared to the group of patients with high levels of good cholesterol.

The findings demonstrate that high levels of HDL help reduce formation of beta-amyloid in the protein plaques associated with Alzheimer's disease.

Dr Singh-Manoux concluded: "Many previous investigations into the association between lipids and memory in the elderly have focused on total or LDL cholesterol because of their status as proven risk factors for cardiovascular disease.

Our results show HDL cholesterol to be important for memory. Thus, physicians and patients should be encouraged to monitor levels of HDL cholesterol."

Statistics show that neurodegenerative diseases such as Alzheimer's, most commonly affect people over the age of 65.

Login and visit the Alzheimer's Disease Knowledge CentreLogin and visit the Cholesterol Knowledge Centre

• Blood sugar warning for the prevention of Alzheimer's 30/12/08
• Brain starvation seems to trigger Alzheimer's, study suggests 29/12/08
• Plans for new Alzheimer's clinics unveiled 24/12/08
• Cardiovascular proteins found to work together to speed up Alzheimer's 22/12/08
• Research looks at strategy games in the prevention of cognitive deterioration 12/12/08

• EBIXA 10mg film-coated tablets - 50.88%
  Treatment of patients with moderately severe to severe Alzheimers disease ...
  
  
• CERETEC - 26.56%
  ... the diagnosis of abnormalities of regional cerebral blood flow, such as those occurring following stroke and other cerebrovascular disease, epilepsy, Alzheimer's Disease and other forms of dementia, transient ischaemic attack, migraine and tumours of the brain. (ii) Technetium [99mTc] Exametazime ...
  
  
• EBIXA 10 mg/g oral drops, solution - 25.26%
  Treatment of patients with moderate to severe Alzheimer's disease ...
  
  
• EXELON Capsules - 25.26%
  Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease ...
  
  
• CEREZYME 400 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...
  
  
• CEREZYME 200 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...